Raymond James Financial RJF
Financial Services · Asset Management · Synthos Deep Dive · 2026-07-03
The Overview
Raymond James is a big financial firm that does three main things: it employs thousands of financial advisors who manage everyday people's investment accounts (that's the biggest part), it runs a bank that makes loans, and it helps companies raise money and do deals (investment banking). It earns fees on the roughly $1.76 trillion of client money it looks after, plus interest on its bank loans.
Is the stock cheap or expensive? Fairly priced — right in the middle. You pay about $15 for every $1 the company earns in a year, which is reasonable for a solid, profitable business. It is not a bargain, and it is not wildly overpriced.
Our verdict is Watch — a good company we would happily own at the right price, but today's price does not offer a clear bargain, and no expert we track has flagged it as a special opportunity.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe). The company has more cash than debt and its stock is not especially jumpy — but its earnings rise and fall with the stock market and interest rates, so a bad market year would dent profits.
- Growth Quality 6/10 (good, not great). It grows steadily and earns strong returns, but it grows at the pace of markets and its advisor headcount — no explosive engine.
- Exponential Potential 3/10 (low). This is a mature, large company. Expect steady growth, not a rocket.
The one big worry: almost every way this company makes money — advisory fees, trading, deal-making, loan interest — gets worse at the same time when markets fall or interest rates drop sharply.
Putting a number on it: our fair-value estimate is $178 against a current price of $179.36 — consistent with our call to stay away or wait for a better setup.
Our summary metrics
Net-cash balance sheet, beta 0.95, cheap 15× P/E — but market-cyclical revenue (IB, trading, spread income) and rate-sensitive NII.
~13% forward EPS CAGR, 17% ROE, record fee-based assets — but growth is steady-cyclical, not secular.
Big-but-mature wealth/brokerage franchise; growth is decelerating off the rate peak and cap is well past multibagger range.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Big-but-mature wealth/brokerage franchise; growth is decelerating off the rate peak and cap is well past multibagger range.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $160.5 (high $166 / low $155; 1 Strong Buy · 9 Buy · 14 Hold · 0 Sell — consensus "Hold") — context, not our anchor |
| Valuation | 15.1× trailing EPS · 13.7× FY26E · 11.9× FY27E · 8.2× FY29E · EV/EBITDA 8.7× · P/B 2.5× |
| Technicals | Mild uptrend — $162.66, −7.8% off 52-wk high, above 50-DMA, ~at 200-DMA, RSI 68, +5% 12-mo (SPY +21%) |
| Conviction | None from the KB — 0 expert voices, 0 claims. Verdict rests on quant + fundamentals only |
| Position sizing | If owned, a ~1–3% quality-financials sleeve position; not a high-conviction overweight |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for RJF — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $179.36, 5% above the 50-day average ($170), 12% above the 200-day average ($160) — an uptrend. 1% below the 52-week high of $181, 27% above the 52-week low of $141.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $179.36 is currently inside the band (band $174–$183).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 59.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.72, negative momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = RJF · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Raymond James Financial (NYSE: RJF) is a diversified financial-services firm founded in 1962, headquartered in St. Petersburg, Florida, with ~24,600 employees. It operates across the US, Canada, and Europe. Fiscal year ends September 30. The business is built on four reporting segments:
- Private Client Group (PCG) — the core: a large network of financial advisors serving retail clients, earning asset-management/advisory fees, commissions, and spread on client cash. This is the ballast of the firm.
- Capital Markets — investment banking (equity/debt underwriting, M&A advisory) and fixed-income/equity brokerage. The most cyclical, market-sensitive segment.
- RJ Bank — insured deposits and lending (commercial, CRE, residential mortgage, and securities-based loans).
- Asset Management — fee-based portfolio/asset management for retail and institutional clients.
Revenue mix (FY2025, from FMP segmentation — total gross segment revenue):
- By segment: Private Client Group $10.28B (~63%) · RJ Bank $3.38B (~21%) · Capital Markets $1.87B (~11%) · Asset Management $1.19B (~7%). The firm is overwhelmingly a wealth-management business with a capital-markets and banking overlay.
- By geography: United States $12.87B (~91%) · Canada $0.65B (~5%) · Europe $0.55B (~4%). Heavily US-centric.
The structural story: recurring, fee-based advisory revenue (which grows with markets and net new assets) provides ballast, while investment banking, trading, and net interest income add cyclical torque on top. Per management's Q2 FY26 release, client assets under administration reached $1.76 trillion and PCG fee-based accounts hit a record $1.04 trillion.
2. The expert thesis — why the panel is bullish (traceable)
There is none in our knowledge base. The Synthos KB contains 0 claims on RJF, 0 net-bullish voices, and 0 cautionary voices (total_claims: 0). No expert we track — bullish or bearish — has an on-record, distilled view on Raymond James.
This is stated plainly and honestly per the house standard: the RJF verdict is entirely fundamentals- and quant-driven. We cite no claim_id values because none exist to cite. Fabricating conviction here would violate the one rule that makes this research trustworthy. Readers should weight this note accordingly: it reflects the numbers and our scenario model, not a panel of independent voices, and it carries correspondingly lower conviction than a name like our flagship holdings where a dozen analysts have spoken.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Net cash (net debt −$6.8B, net-debt/EBITDA −2.0×), beta 0.95, cheap 15× P/E, A- letter rating, and a fortress capital position (Tier 1 leverage 12.4%). Offset: revenue is genuinely cyclical — IB fees, trading, and net interest income all fall together in a downturn. |
| Growth Quality | 6 · Good | ~13% forward EPS CAGR (FY25→FY29E), 17.2% ROE, record fee-based assets, disciplined buybacks. But growth is steady-cyclical, tied to market levels and advisor recruiting — not a secular compounding engine. |
| Exponential Potential | 3 · Low | A mature $31B franchise. Growth is decelerating off the 2023–24 rate peak (NII tailwind is now a mild headwind). No credible path to a multibagger from here. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. The cases bound the range; the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Markets stay strong; net new assets accelerate; IB pipeline converts; NII stabilizes. FY27E EPS beats to ~$14.7 (vs $13.71 cons); multiple re-rates to ~14.5× on visible growth. | ~$214 (+32%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$13.7; a steady mid-teens-ROE compounder earns a ~13× through-cycle multiple. | ~$178 (+9%) |
| Bear | Market/rate downturn: fee assets fall, IB freezes, NII compresses, credit costs rise. FY27E EPS misses to ~$11.4; multiple de-rates to ~11.2×. | ~$128 (−21%) |
Synthos fair value = the base case, ~$178 (+9%), with the full $128–$214 span as the honest range. This anchor sits modestly above the Street's $160.5 consensus (we give some credit to the FY27 earnings path and buyback-driven share-count reduction), but the upside is thin enough — and the KB conviction absent enough — that the verdict is Watch, not Buy. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating multi-baggers-from-here). RJF is a solid compounder with low exponential potential:
- Forward growth: revenue CAGR FY25→FY29E ~6.5% ($15.9B → $20.5B est); EPS CAGR ~13% ($10.30 → ~$19.94 est) as buybacks shrink the share count and margins hold. Respectable, but market-paced.
- Acceleration (the 2nd derivative) is negative: revenue grew +44% cumulatively FY20→FY25 on the rate-hike NII windfall and market appreciation, but forward estimates imply high-single-digit revenue growth — a clear deceleration as the interest-rate tailwind fades to neutral/headwind. Per our flagship philosophy we pick forward next-exponentials over trailing compounders — RJF is firmly the compounder, not the exponential.
- Room to run: wealth management is a large, competitive market and RJF is already a top-tier player at $1.76T AUA. At a $31.7B cap, a 5× would imply a ~$160B firm — larger than Charles Schwab's current cap. Not a realistic multibagger runway.
- Reinvestment runway: growth comes from advisor recruiting, tuck-in M&A (e.g. the GreensLedge acquisition closed in Q2 FY26), and organic net new assets — steady, capital-light, but not exponential.
Exponential Potential: Low (3/10). Own RJF, if at all, for steady mid-teens-ROE compounding plus a rising dividend and buyback — not for a fast multibagger. A small, accelerating name would score far higher on this axis; RJF is the opposite profile.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $15.91B, +7.9% (FY24 $14.74B, +14.8% on FY23 $12.84B). Steady growth; the FY22→FY24 surge was rate-driven NII plus market appreciation.
- Quarterly trajectory: Q1 FY26 (Dec-25) $4.18B → Q2 FY26 (Mar-26) $4.26B (+13% YoY per management). Record first-half net revenues of $7.59B (+9%).
- Margins: gross ~89% (accounting artifact for a financial), EBITDA margin ~18% TTM, pre-tax margin ~17%, net margin ~13.1% TTM. Solid for a diversified broker-dealer.
- Earnings: net income $2.13B FY25 (EPS diluted $10.30); TTM net income ~$2.25B, TTM EPS ~$10.95. Q2 FY26 EPS diluted $2.72 ($2.83 adjusted).
- Returns on capital: ROE 17.2% TTM, ROA ~2.3% (low ROA is normal for a bank/broker balance sheet), ROIC ~8.0%. Management cites annualized adjusted return on tangible common equity of 20.9% for Q2 FY26 — genuinely strong.
- Cash flow: operating CF $2.43B FY25, capex ~−$0.19B, FCF $2.25B — high FCF conversion. (Note: broker-dealer operating cash flow is volatile quarter to quarter due to client-related working-capital swings; FY23 showed a large negative OCF from a payables swing that reversed — not an operating problem.)
- Balance sheet: total debt $4.55B against $18.3B cash & short-term investments → net cash of ~$6.8B (net-debt/EBITDA −2.0×). Total capital ratio 24.0%, Tier 1 leverage 12.4% — well above regulatory minimums. A- letter rating.
6. Valuation — priced in or room?
RJF is reasonably, not cheaply, valued. On trailing numbers: 15.1× EPS, 2.5× book, ~1.9× sales, 8.7× EV/EBITDA. On forward consensus the P/E steps down as EPS grows and the share count shrinks: 13.7× FY26E → 11.9× FY27E → ~10.2× FY28E → 8.2× FY29E. That forward compression is the crux of any bull case — you are not overpaying, and buybacks (the firm repurchased $400M at ~$155/share in Q2 FY26, with $1.5B authorization remaining) steadily lower the denominator.
But "not overpaying" is not the same as "bargain." A ~15× multiple on a mid-teens-ROE cyclical financial is roughly fair value, which is exactly why the Street sits at a "Hold" (1 Strong Buy, 9 Buy, 14 Hold, 0 Sell) with a $160.5 consensus target — essentially at the current $162.66 price. Street targets (context, not our anchor): consensus $160.5, high $166, low $155 — an unusually tight band that signals a "fairly valued, few surprises" read. Our $178 base FV is a touch more constructive on the FY27 earnings path, but the ~9% base-case upside is thin. Not a value dislocation; a fairly-priced quality compounder.
7. Technicals (from the FMP tech block)
- Trend: mildly up. $162.66 sits above the 50-DMA ($153.04) and just above the 200-DMA ($158.24), with the 50 below the 200 (the average cross posture is still healing after a flat 6 months) — a modest uptrend, not a powerful one.
- Location: −7.8% off the 52-week high ($176.43), +15.5% off the 52-week low ($140.89). Max drawdown from peak a shallow −7.8% — a low-volatility name.
- Momentum: RSI(14) 67.6 — strong, approaching but not yet overbought (<70). MACD +1.33 (mildly positive). The +2.8% move on the quote day nudged it toward the top of its recent range.
- Relative strength (the tell): RJF +5.2% 12-mo vs SPY +20.6% and QQQ +30.3% — a clear laggard over the past year, and flat over 6 months (+0.07%). It did keep pace over 3 months (+13.4% vs SPY +13.7%). This is a defensive, market-lagging profile, consistent with the fundamentals.
- Read: technicals are neutral-to-mildly-constructive — an orderly, low-drawdown name reclaiming its 200-DMA, but a 12-month underperformer with no momentum edge. No urgency to chase; RSI near 68 argues against buying the day's spike.
8. Moat & competitive position
RJF's competitive advantage is a sticky advisor-and-client network with high switching costs: advisors who join Raymond James (drawn by its multi-affiliation model and culture) bring durable client relationships, and the fee-based asset base ($1.04T and rising) compounds with markets and net new assets. The bank and asset-management arms deepen the client relationship and monetize client cash. It is a wide-enough moat within a competitive, fragmented industry — real, but not a monopoly; the constraints are advisor recruiting competition, fee compression, and cash-sweep economics.
Peer set (from FMP, market cap): Morgan Stanley $337B and Charles Schwab $169B (the large-cap wealth/brokerage comps), LPL Financial $23.6B (the closest independent-broker-dealer comp), State Street $47B, Sun Life $44B, NatWest $36B, Arch Capital $36B, Willis Towers Watson $27B, Futu $13B. Against LPL and Schwab, RJF sits mid-pack on growth and valuation — cheaper than LPL's growth multiple, less scaled than Schwab, more conservative on the balance sheet than most. A quality, middle-of-the-fairway operator.
9. Management, capital allocation & guidance
- Leadership: CEO Paul Shoukry (a relatively recent CEO transition from long-time leader Paul Reilly). Founder-family influence remains — 10%-owner Thomas A. James (Form 3 filings 2026-06-26) — which historically aligns with conservative, long-term stewardship.
- Capital allocation: disciplined and shareholder-friendly. Q2 FY26: $400M of buybacks at ~$155/share ($1.5B authorization remaining), $81M preferred redeemed, a growing dividend ($2.08/share, ~1.3% yield, ~20% payout — plenty of room). Tuck-in M&A (GreensLedge, closed Q2 FY26) supplements organic growth. Capital ratios are well above regulatory minimums — capital return is sustainable through a cycle.
- Insider activity: the June 2026 filings are Form 3 ownership statements from 10%-owner Thomas A. James (holdings disclosure, not open-market sales). One routine officer sale (Chief Admin Officer, 29,551 shares at $142.34, March 2026). No alarming cluster of discretionary insider selling in the sampled window.
- Management's own guidance (half-weighted — their own book): the SEC 8-K earnings release (Q2 FY26, dated 2026-04-22) is a real earnings release (revenue, segment results, capital ratios), but RJF does not issue explicit numeric forward EPS/revenue guidance — typical for a broker-dealer whose results depend on markets. Management's forward-looking commentary (half-weighted, their self-interested words): CEO Shoukry said "financial advisor recruiting activity across all our affiliation options remains robust, and the investment banking pipeline continues to be strong," and highlighted increasing AI integration to improve advisor efficiency. Treat as directional optimism, not committed numbers. Bottom line: no hard management guidance is available; the forward figures in this note are analyst consensus (FMP), labeled as estimates.
10. Catalysts & what to watch
- Next earnings: 2026-07-22 (Q3 FY26; Street EPS $2.91, revenue ~$3.87B). Key lines: net new assets, PCG fee-based asset growth, net interest margin (2.81% last quarter), and investment banking revenue (the swing factor).
- Interest-rate path: RJF's NII and cash-sweep economics are rate-sensitive; further Fed cuts pressure spread income even as they can lift markets/fee assets — a genuine two-sided lever.
- Investment banking cycle: a sustained recovery in underwriting and M&A (management says the pipeline is "strong") would drive the Capital Markets segment's upside.
- Advisor recruiting & net new assets: the organic-growth engine; watch the annualized NNA rate (5.8% domestic PCG in Q2 FY26).
- Buyback pace: $1.5B remaining authorization — accelerated repurchases at a low multiple are accretive.
Thesis tripwires (what would change the call): two consecutive quarters of net-new-asset deceleration or fee-asset outflows; a sharp NIM compression below ~2.5%; a credit-quality deterioration in the loan book; or a market drawdown that freezes the IB pipeline. Conversely, a pullback toward ~$145 (a cheaper ~11× FY27E) or the arrival of genuine expert coverage would move this toward Buy.
11. Key risks
- Cyclicality (the structural one): nearly every revenue line — advisory fees (tied to market levels), trading, investment-banking fees, and net interest income — deteriorates together in a market or rate downturn. This is the defining risk and the reason for the moderate Downside Risk score despite the fortress balance sheet.
- Rate sensitivity: falling short rates compress cash-sweep and bank NII; management already notes lower interest-related revenues weighing on PCG pre-tax income.
- Credit risk: RJ Bank's $54.8B loan book (CRE, C&I, residential, securities-based) carries cycle-dependent credit costs; quality is currently strong but is a watch item.
- Fee compression / competition: the wealth-management industry faces persistent fee pressure and intense advisor-recruiting competition (Schwab, LPL, Morgan Stanley, wirehouses).
- No expert coverage / lower conviction: with 0 KB claims, this note lacks the independent-voice corroboration that anchors our high-conviction calls — a meta-risk to the thesis itself.
- Valuation offers little cushion: at ~15× and ~9% base-case upside, there is limited margin of safety if estimates slip.
12. Verdict, position sizing & monitoring
Watch. Raymond James is a genuinely well-run, conservatively-financed financial franchise — net cash, 17% ROE (21% on tangible common equity), record fee-based assets, disciplined buybacks, A- rating, and a reasonable ~15× multiple. There is little to dislike about the business. But the setup does not clear our Buy bar: the stock is fairly (not cheaply) priced with ~9% base-case upside, it has lagged the market badly over 12 months, the Street itself sits at "Hold," and — decisively for a conviction-driven shop — no expert in the Synthos KB covers it. We would be buyers on a pullback or on the arrival of a credible expert thesis; today it is a name to track, not chase.
- Sizing: if owned as a quality-financials holding, ~1–3% — a steady-eddy position, not a high-conviction overweight. A better entry (~$145 / ~11× FY27E) would improve the risk/reward.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print (next: 2026-07-22). This verdict is logged as a tracked Synthos call as of 2026-07-03 at $162.66.
- Single biggest risk: cyclicality — a market/rate downturn hits fees, trading, deal-making, and net interest income simultaneously.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — no expert coverage exists for RJF in the Synthos KB. The verdict is explicitly quant- and fundamentals-driven; no
claim_idis cited because none exists. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we do not manufacture it here. - Data as-of: fundamentals 2026-03-31 (Q2 FY26) · estimates & prices 2026-07-02/03 · SEC 8-K earnings release 2026-04-22. Forward figures are analyst consensus (FMP), labeled as estimates.
- Management caveat: RJF issues no explicit numeric forward guidance; management's forward commentary (recruiting/IB pipeline) is half-weighted as their own self-interested words.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").